Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2007.08.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibitory effects of calcium channel blockers nisoldipine and nimodipine on ivacaftor metabolism and their underlying mechanism.
Front Pharmacol
September 2024
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ivacaftor is the first potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein approved for use alone in the treatment of cystic fibrosis (CF). Ivacaftor is primarily metabolized by CYP3A4 and therefore may interact with drugs that are CYP3A4 substrates, resulting in changes in plasma exposure to ivacaftor. The study determined the levels of ivacaftor and its active metabolite M1 by ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS).
View Article and Find Full Text PDFA proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling.
Clin Pharmacokinet
December 2009
Pharmacology and Pharmacokinetics, University of Tokyo Hospital, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Background And Objective: Pharmacokinetic drug-drug interactions (DDIs) are one of the major causes of adverse events in pharmacotherapy, and systematic prediction of the clinical relevance of DDIs is an issue of significant clinical importance. In a previous study, total exposure changes of many substrate drugs of cytochrome P450 (CYP) 3A4 caused by coadministration of inhibitor drugs were successfully predicted by using in vivo information. In order to exploit these predictions in daily pharmacotherapy, the clinical significance of the pharmacokinetic changes needs to be carefully evaluated.
View Article and Find Full Text PDFTransient exposure to hydrogen peroxide causes an increase in mitochondria-derived superoxide as a result of sustained alteration in L-type Ca2+ channel function in the absence of apoptosis in ventricular myocytes.
Circ Res
April 2007
School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, 35 Stirling Hwy, Crawley, WA, 6009, Australia.
We sought to understand the effect of a transient exposure of cardiac myocytes to H(2)O(2) at a concentration that did not induce apoptosis. Myocytes were exposed to 30 micromol/L H(2)O(2) for 5 minutes followed by 10 U/mL catalase for 5 minutes to degrade the H(2)O(2). Cellular superoxide was measured using dihydroethidium.
View Article and Find Full Text PDFInstability of calcium channel antagonists during sample preparation for LC-MS-MS analysis of serum samples.
Forensic Sci Int
January 2006
Departamento de Química Analítica, Facultad de Ciencia y Tecnología, Universidad del País Vasco/EHU, Apdo. 644, E-48080 Bilbao, Spain.
1,4-Dihydropyridines calcium channel antagonists (1,4-DHP CCAs) are photolabile and the products of their photodecomposition have no pharmaceutical activity. In our previous work we have presented a screening procedure for eleven 1,4-DHPs in plasma by LC-MS-MS using multiple reaction motoring. The laboratory process includes preparation and storage of stock solutions, plasma storage, solid-phase extraction, reconstitution of extracts and storage time in an autosampler for LC-MS-MS analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!